Monsanto Company (NYSE:MON) announced today that it has successfully completed its third year of collaborative research with Evogene Ltd. Using its computational genetics technology, Evogene has discovered genes while predicting and providing validation in the model’s chosen plants for Monsanto.
In this five-year study, the two companies are attempting to discover genes that will enhance crop yields in corn, soybean, cotton and canola for farmers. For the project, Evogene is looking at key plant genes for yield, environmental stress, and fertilizer utilization for Monsanto to evaluate and develop commercially. During the next two years, Evogene will look at additional performance data for the selected genes and also consider additional products for farmers to grow through Monsanto’s help.
Monsanto’s stock (NYSE:MON) is down 1.96% to $64.57 in the market crash. Shares are down 7.31% year to date. The stock has traded in a 52-week range between $47.07 and $77.09.
Competitors to Watch: SSyngenta AG (NYSE:SYT), The Scotts Miracle-Gro Co. (NYSE:SMG), The Dow Chemical Company (NYSE:DOW), FMC Corporation (NYSE:FMC), The Mosaic Company (NYSE:MOS), American Vanguard Corp. (NYSE:AVD), Potash (NYSE:POT), CF Industries Hldgs., Inc. (NYSE:CF) and Origin Agritech Ltd. (NASDAQ:SEED).